Publications by authors named "A Mirouse"
Article Synopsis
- A study compared the effectiveness and safety of infliximab and cyclophosphamide as induction therapies for severe Behçet's syndrome involving major vascular or CNS issues.
- Infliximab showed a higher complete response rate (81%) compared to cyclophosphamide (56%), indicating it may be more effective.
- Additionally, infliximab had fewer adverse events (29.6%) compared to cyclophosphamide (64%), suggesting it may also be safer for patients.
Objective: To assess the prognosis and outcome of patients with isolated carotid vasculitis.
Methods: We performed a retrospective multicenter study of 36 patients (median age at diagnosis was 37 [IQR 27-45] years and 11 [31 %] patients were men) with initial presentation as isolated carotid vasculitis. Study endpoints included vascular complications, relapses, and progression to large vessel vasculitis (i.
Fibrillary glomerulonephritis (FGN) is a glomerular disease described since 1977, with a prevalence in renal biopsies of less than 1%. It presents as renal failure, proteinuria, haematuria and hypertension in middle-aged adults. It is defined histologically, using light microscopy, which reveals organised deposits of fibrils measuring around 20nm, which are negative for Congo red staining.
View Article and Find Full Text PDFWe conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharmacovigilance database, we estimated the RR of PMR and GCA cases in individuals aged over 50 who developed their initial symptoms within one month of receiving the BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCoV-19, and Ad26.COV2.
View Article and Find Full Text PDF